Physician profile
Eric J Meaux
NPI 1467959718
$3,425.30
in general payments reported to CMS, 2019-2025
27 companies · $546 in 2025
The $546 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $900 · 2022: $1,039 · 2023: $516 · 2024: $424 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,310.96 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $531.92 | 2021-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $503.40 | 2021-2025 | |
| Amgen INC. | $378.20 | 2021-2025 | Prolia, Evenity, Prolia |
| Merck Sharp & Dohme LLC | $324.38 | 2021-2025 | Verquvo, Dificid, Steglatro |
| Lilly USA, LLC | $259.52 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.75 | 2021-2025 | Jardiance |
| Neurocrine Biosciences, INC. | $154.06 | 2022 | |
| Sanofi-Aventis U.S. LLC | $142.83 | 2021-2022 | |
| Mylan Specialty L.P. | $131.80 | 2021-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $126.37 | 2021-2023 | |
| Pfizer INC. | $123.41 | 2022-2024 | |
| Abbvie INC. | $74.91 | 2021-2023 | |
| Verona Pharma, INC. | $69.37 | 2025 | Ohtuvayre |
| Esperion Therapeutics, INC. | $67.49 | 2023-2025 | Nexletol |
| Seqirus USA INC | $60.29 | 2024 | Flucelvax, Fluad |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $42.97 | 2021-2023 | Freestyle Libre 3 |
| Avanir Pharmaceuticals, INC. | $42.61 | 2022 | |
| Lundbeck LLC | $42.46 | 2023-2025 | Rexulti |
| Acadia Pharmaceuticals INC | $32.29 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.17 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $19.82 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $17.74 | 2021 | |
| Exact Sciences Corporation | $15.55 | 2025 | The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $14.93 | 2024 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $14.62 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.33 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Meaux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.